Former Board Member Files Intent to Sell $149K in Shares Amid Going Concern Warning
CLNN has more than doubled off its 52-week low of $2.28.
Summary
Symbiosis II LLC, a former board member and entity associated with a 10% owner, filed a Form 144 to sell 30,518 shares of Clene Inc. worth approximately $149,233, continuing a pattern of insider selling while the company faces a "going concern" warning.
Key Events · Ownership and Investor Activity · CLNN
-
Proposed Share Sale
Symbiosis II LLC, a former board member and entity associated with a 10% owner, intends to sell 30,518 common shares valued at approximately $149,233.
-
Ongoing Insider Selling Pattern
This filing continues a pattern of share disposition by the same entity, following a Form 144 on March 24, 2026, and aligns with recent insider sales by a 10% owner, Ugwumba Chidozie, on March 31, 2026.
-
Going Concern Context
The intent to sell comes shortly after the company's 10-K filing disclosed substantial doubt about its ability to continue as a going concern, amplifying the negative signal of insider selling.
Analysis · CLNN · Life Sciences
This Form 144 filing from Symbiosis II LLC, an entity associated with a 10% owner and former board member, signals a continued pattern of insider share disposition. The proposed sale of approximately $149,233 in shares, while not individually massive, is significant in the context of Clene Inc.'s recent 10-K filing which expressed substantial doubt about its ability to continue as a going concern. This ongoing insider selling, following a previous Form 144 from the same entity on March 24, 2026, and a Form 4 from a 10% owner on March 31, 2026, suggests a lack of insider confidence at a critical juncture for the company. Investors should view this as a negative signal, especially given the company's financial uncertainties.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 29.2% of the 1541 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLNN was trading at $4.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.1M. The 52-week trading range was $2.28 to $13.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.